Postmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 8, 2014, Pages 919-922

  Newman, P K ^a   Todd, N V ^b   Scoones, D ^a   Mead, S ^c   Knight, R S G ^d   Will, R G ^d   Ironside, J W ^d  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b Department of Neurosurgery   (United Kingdom)

^c National Prion Clinic   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOSAN POLYSULFATE; PRION PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; ATAXIC GAIT; AUDITORY HALLUCINATION; AUTOPSY; BRAIN ATROPHY; BRAIN LEVEL; BRONCHOPNEUMONIA; CLINICAL ARTICLE; COGNITIVE DEFECT; DELUSION; DEVICE INFECTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DYSARTHRIA; FEMALE; GLIOSIS; HEMATOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFUSION PUMP; LUNG EDEMA; MEDICAL HISTORY; NEUROPATHOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SURVIVAL TIME; VARIANT CREUTZFELDT JAKOB DISEASE; ADOLESCENT; BRAIN; CASE REPORT; CREUTZFELDT JAKOB DISEASE; CREUTZFELDT-JAKOB DISEASE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PRION; SURVIVAL;

CREUTZFELDT-JAKOB DISEASE; NEUROPATHOLOGY; PRION;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOPSY; BRAIN; CREUTZFELDT-JAKOB SYNDROME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; PENTOSAN SULFURIC POLYESTER; PRIONS; SURVIVAL;

EID: 84904182357     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305590     Document Type: Article

References (14)

1. Haik S, Brandel JP, Salomon BA, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004;63:2413-15.
2. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009;8:334-44.
3. Doh-ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004;78:4999-5006.
4. Whittle IR, Knight RSG, Will RG. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir (Wien) 2006;148:677-9.
5. Parry A, Baker I, Stacey R, et al. Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. JNNP 2007;78:733-4.
6. Todd NV, Morrow J, Doh-ura K, et al. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infection 2005;50:394-6.
7. Bone I, Belton L, Walker AS, et al. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. European J Neurology 2008;15:458-64.
8. Terada T, Tsuboi Y, Obi T, et al. Less protease-resistant PrP in a patient with sporadic treated with intraventricular pentosan polysulphate. Acta Neurol Scand 2010;121:127-30.
9. Heath CA, Cooper SA, Murray K, et al. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann Neurol 2010;67:761-70.
10. Edgeworth JA, Farmer M, Sicilia A, et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 2011;377:487-93.
11. Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004;203:733-9.
12. Peden A, McCardle L, Head MW, et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010;16:296-304.
13. Pocchiari M, Puopolo M, Croes E, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004;127:2348-59.
14. Trewby PN, Chipping PM, Palmer SJ, et al. Splenic atrophy in adult coeliac disease: is it reversible? Gut 1981;22:628-32.